Yes I did. The New York Health Dept. does not say that. Show us where it prioritizes non-whites.
Prioritization of Anti-SARS-CoV-2 Monoclonal Antibodies and Oral Antivirals for the Treatment of COVID-19 During Times of Resource Limitations Introduction In times of limited supplies of monoclonal antibodies (mAbs) and oral antivirals (OAVs), providers should prioritize patients eligible for treatment based on their level of risk for progressing to severe COVID-19. In addition, the most efficacious products should be prioritized for patients with the highest risk for hospitalization and death. 1 According to the NIH COVID-19 Treatment Guidelines, triage and prioritization should only be implemented when logistical or supply constraints make it impossible to offer the therapy to all eligible patients. During periods of limited resources, the Panel suggests: • Prioritizing the treatment of COVID-19 and • Prioritizing anti-SARS-CoV-2 mAbs and OAVs for unvaccinated or incompletely vaccinated individuals and vaccinated individuals who are not expected to mount an adequate immune response (e.g., individuals with moderate to severe immunocompromise or individuals aged ≥65 years). As reminder, Monoclonal antibodies and oral therapeutics are not a substitute for vaccination in individuals for whom vaccination is recommended. Providers should continue recommending COVID-19 vaccination as the best strategy to prevent COVID-19 severe disease, hospitalizations, and deaths. Patients who have moderate to severe immune compromise (due to a medical condition or receipt of immunosuppressive medications or treatments) or are unable to receive COVID-19 vaccines due to a history of a severe adverse reaction to a COVID-19 vaccine should be considered for pre-exposure prophylaxis with a long-acting monoclonal antibody (Evusheld). How to use this framework Each patient should be assigned to a group within Tier 1 and then prioritized within the respective group. Patients assigned to 1A should be considered the highest priority, with 1B being the next highest priority and so on. The recommended therapy section notes which groups should receive therapy without exception and which groups may need to be put on a wait list if supplies of a given